Hemogenyx Pharmaceuticals Plc (LON:HEMO)
London flag London · Delayed Price · Currency is GBP · Price in GBX
177.25
-0.90 (-0.51%)
Jun 6, 2025, 4:50 PM BST

Hemogenyx Pharmaceuticals Company Description

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer.

The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia.

It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures.

Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.

Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals logo
Country United Kingdom
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Vladislav Sandler

Contact Details

Address:
6 Heddon Street
London, W1B 4BT
United Kingdom
Website hemogenyx.com

Stock Details

Ticker Symbol HEMO
Exchange London Stock Exchange
Fiscal Year January - December
Reporting Currency GBP
ISIN Number GB00BYX3WZ24
SIC Code 2836

Key Executives

Name Position
Dr. Vladislav Sandler Ph.D. Co-Founder, Chief Executive Officer and Director
Alexis M. Sandler J.D. Independent Co-Founder and Non-Executive Director
Dr. Koen Van Besien M.D., Ph.D. Clinical Advisor and Medical Director
Ben Harber Company Secretary